Date:4/30/2009

es 25,273 16,817 Site support 7,775 6,260 Total net revenues 33,673 23,786 Costs of revenues: Cost of licenses 200 205 Cost of services 10,514 7,954 Cost of site support 5,268 3,635 Total costs of revenues 15,982 11,794 Gross margin 17,691 11,992 Operating expenses: Selling and marketing 3,323 3,426 General and administrative 4,873 4,077 Research and development 999 1,149 Total operating expenses 9,195 8,652 Operating income 8,496 3,340 Other income, net 427 116 Income before income taxes 8,923 3,456 Income tax provision 3,177 1,386 Net income $5,746 $2,070 Basic net income per share $0.11 $0.04 Diluted net income per share $0.11 $0.04 Shares used to calculate basic net income per share 50,638 50,879 Shares used to calculate diluted net income per share 51,894 51,164

                   eResearchTechnology, Inc. and Subsidiaries
                            Consolidated Balance Sheets
               (in thousands, except share and per share amounts)

                                        December 31,
'/>"/>
SOURCE  eResearchTechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 
Related biology technology :

1. CryoLife Reports Record First Quarter Revenues of $26.7 Million
2. Caliper Life Sciences Reports First Quarter 2009 Results
3. Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets
4. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
5. Vanda Pharmaceuticals Reports First Quarter 2009 Results
6. Telik Reports Preclinical Results at AACR Annual Meeting
7. PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results
8. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
9. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
10. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
11. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights